Exscientia, a pioneer in the use of Artificial Intelligence (AI) in drug discovery and one of Frontier’s core portfolio companies, has announced that it has raised US$26m in a Series B funding round which includes participation from new investors Celgene Corporation and GT Healthcare Capital Partners, as well as from existing investor Evotec AG. It has also announced a drug discovery collaboration with Roche worth up to CHF 67m in upfront and research funding. Post the funding round Frontier’s s ....
